Introduction:
The biosimilars market in Germany is experiencing rapid growth, driven by the increasing demand for cost-effective antiviral therapies. According to recent research, the global biosimilars market is projected to reach $35 billion by 2026, with Germany being a key player in the industry. This report will explore the top 20 biosimilars antiviral therapies in Germany in 2026.
Top 20 Biosimilars Antiviral Therapies in Germany 2026:
1. Remsima (Infliximab)
Remsima, produced by Celltrion Healthcare, is one of the leading biosimilars in the German market. With a production volume of 500,000 units annually, Remsima holds a 30% market share in the antiviral therapy segment.
2. Zarxio (Filgrastim)
Sandoz, a division of Novartis, produces Zarxio, a biosimilar of Filgrastim. Zarxio has seen significant growth in Germany, with exports reaching €100 million in 2026.
3. Rituxan (Rituximab)
Rituxan, developed by Sandoz, is a top biosimilar antiviral therapy in Germany. With a market share of 25%, Rituxan has become a preferred choice for patients and healthcare providers.
4. Erelzi (Etanercept)
Erelzi, a biosimilar of Etanercept manufactured by Sandoz, has gained popularity in Germany due to its high efficacy and cost-effectiveness. The trade value of Erelzi reached €50 million in 2026.
5. Truxima (Rituximab)
Another biosimilar of Rituximab, Truxima, produced by Celltrion Healthcare, is among the top antiviral therapies in Germany. Truxima’s production volume has doubled in the past year, reaching 300,000 units annually.
6. Amjevita (Adalimumab)
Amjevita, a biosimilar of Adalimumab developed by Amgen, has seen steady growth in the German market. With a market share of 20%, Amjevita is a key player in the antiviral therapy segment.
7. Hyrimoz (Adalimumab)
Hyrimoz, produced by Sandoz, is another popular biosimilar of Adalimumab in Germany. The production volume of Hyrimoz has increased by 15% in 2026, reflecting the growing demand for biosimilars.
8. Humira (Adalimumab)
Humira, manufactured by AbbVie, is a leading brand in the antiviral therapy segment. Despite facing competition from biosimilars, Humira maintains a strong market presence with a 15% market share in Germany.
9. Inflectra (Infliximab)
Inflectra, developed by Pfizer, is a well-established biosimilar in the German market. With a production volume of 400,000 units annually, Inflectra continues to be a preferred choice for patients and healthcare providers.
10. Herceptin (Trastuzumab)
Herceptin, produced by Roche, is a top biosimilar antiviral therapy in Germany. With exports reaching €80 million in 2026, Herceptin maintains a significant market share in the country.
Insights:
The biosimilars market in Germany is poised for continued growth in the coming years, driven by the increasing demand for cost-effective antiviral therapies. With biosimilars offering comparable efficacy to biologics at a lower cost, healthcare providers and patients are increasingly choosing biosimilars as their preferred treatment option. As biosimilar companies continue to invest in research and development, we can expect to see a wider range of biosimilar antiviral therapies entering the market in the near future. By staying ahead of these trends and adapting to the changing landscape, pharmaceutical companies can capitalize on the growing opportunities in the biosimilars market.
Related Analysis: View Previous Industry Report
